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Dry eye disease or dysfunctional tear syndrome is among the most frequent diagnoses in ophthalmology. It is a multifactorial
diseaseoftheocularsurfaceandtearfilmwhichresultsinoculardiscomfort,visualdisturbances,andtearinstabilitywithpotential
damage to the cornea and conjunctiva. Risk factors for dry eye syndrome include age, sex (female gender), race, contact lens wear,
environmentwithlowhumidity,systemicmedications,andautoimmunedisorders.Theaimofthispaperistopresentthesystematic
classification, epidemiology, diagnostic procedures, and advances in the management of dry eye disease. The recent improvements
in comprehending the underlying etiologic factors will inevitably improve future classifications and diagnostic abilities leading
to more effective therapeutic options. Treatment of this highly prevalent condition can drastically improve the quality of life of
individuals and prevent damage to the ocular surface.
1. Introduction
Dry eye syndrome is recognized as a growing public health
problem and one of the most frequent reasons for seeking
ophthalmologicalintervention.Varioustermshavebeenused
to describe dry eye disease (DED) including keratoconjunc-
tivitis sicca and, more recently, dysfunctional tear syndrome
suggestingthatthenamemoreaccuratelyreflectspathophysi-
ologicalchanges.ThedefinitionofDEDwhichincludesetiol-
ogy, pathophysiology, and symptoms was recently improved
in the light of new findings about the role of tear hyperos-
molarity and ocular surface inflammation in dry eye and its
effect on visual function [1]. According to current knowledge
dry eye can be defined as a multifactorial disease of the tears
a n do c u l a rs u r f a c et h a tr e s u l t si ns y m p t o m so fd i s c o m f o r t ,
visual disturbance, and tear film instability, with potential
damage to the ocular surface. It is accompanied by increased
osmolarity of the tear film and inflammation of the ocular
surface [1, 2].
2. Classification of Dry Eye
Dry eye is a condition that results in dryness of the conjunc-
tiva and cornea due to decreased tear function of tear glands
orrapidevaporationoftears.Onthebasisoftheseunderlying
pathologicprocessesdryeyediseasecouldbeclassifiedastear
deficiency or hyposecretive dry eye which includes Sj¨ ogren’s
syndrome and non-Sj¨ ogren’s tear deficiency and evaporative
orhyperevaporativedryeye(Table 1)[1–4].Thisclassification
often neglects patients with simultaneous occurrence of
hyperevaporation and hyposecretion.
The term “tear-deficient dry eye” implies that this condi-
tion is caused by the lacrimal acinar destruction or dysfunc-
tion with reduced lacrimal tear secretion and volume. This
in turn causes tear hyperosmolarity, since water evaporates
from a reduced aqueous tear pool. Tear film hyperosmolarity
causes hyperosmolarity of the ocular surface epithelial cells
which stimulates a cascade of inflammatory events [1, 2].
Aqueous-deficient dry eye has two major groupings:
Sj¨ ogren’s syndrome and non-Sj¨ ogren’s syndrome dry eye.
Sj¨ ogren’ssyndromeisanexocrinopathyinwhichthelacrimal
and salivary glands as well as other organs are affected
by autoimmune processes and can be divided into two
subgroups:primaryandsecondarySj¨ ogren’ssyndrome.Con-
versely non-Sj¨ ogren’s syndrome is a form of tear deficient
d r ye y ed u et ol a c r i m a ld y s f u n c t i o n ,w h e r et h es y s t e m i c
autoimmune characteristic of Sj¨ ogren’s syndrome has been2 BioMed Research International
Table 1: Classification of dry eye.
Dry eye
Tear deficient (hyposecretive) Evaporative (hyperevaporative)
Sjoergen’s syndrome Non-Sj¨ ogren’s tear deficiency Intrinsic Extrinsic
Primary Lacrimal disease/deficiency Oil deficient Topical drug preservatives
Secondary Lacrimal obstruction Lid related Vitamin A deficiency
Reflex block Low blink rate Contact lens related
Ocular surface change
Drug related
excluded. The most common form is age-related dry eye
[3, 4].
Evaporative dry eye may be intrinsic as a result of
meibomian lipid deficiency, poor lid congruity and lid
dynamics,lowblinkrate,andtheeffectsofdruguse.Extrinsic
evaporative dry eye embraces those etiologies that increase
evaporation including vitamin A deficiency, the action of
toxic topical agents such as preservatives (benzalkonium
chloride), and topical anesthesia. Patient wearing contact
lenses is more prone to have dry eye symptoms. Disease of
the exposed ocular surface including allergic eye disease may
lead to destabilization of the tear film and add a dry eye
component to the ocular surface [1, 2, 5, 6].
3. Prevalence
The prevalence of dry eye symptoms increases with age
and has been reported in approximately 5% to 30% of the
study population depending on the criteria used to define
the condition and the differences in the definition of the
studypopulation[5,7–11].Problemsencounteredintheexact
estimation of prevalence may rely on whether the data came
from general population surveys or physician assessments.
Among patients diagnosed by physicians, estimated preva-
lencemayvarydependingonthediagnosticcriteriausedand
the clinicians’ subjective assessments [12].
In addition to age, the risk factors for development of
dry eye include race or ethnicity; greater incidence is seen
in patients of Chinese, Hispanic, Asian, and Pacific Islands
descent and female sex (women report dry eye twice as
often as men). Women are particularly susceptible to dry eye
symptoms, especially those receiving estrogen replacement
therapy [7]. The prevalence of dry eye is higher in the
presenceofocularconditionssuchasblepharitis,meibomian
gland dysfunction, and conjunctival disease; in the presence
ofsystemicconditionsincludingarthritis,osteoporosis,gout,
and thyroid disorders; and after corneal, retinal, or ocular
oncologic surgery [12, 13].
4. Etiology
The health of the ocular surface is maintained by efficient
production, secretion, and elimination of a physiologically
stable tear film. The tear film has traditionally been con-
sidered to consist of three distinct layers: a thin outer lipid
layer that is secreted by the meibomian glands, an inner
l a y e ro fm u c o u ss e c r e t e db yg o b l e tc e l l so ft h ec o n j u n c t i v a ,
and a complex middle aqueous layer secreted by the main
lacrimal and accessory gland that contains a wide array of
dissolved substances. A newer concept describes the tear
film as a dynamic mucinous gel that decreases in density
toward the outer layer. The tear film maintains the structure
and functioning of the cornea under normal physiological
conditions in individuals with normal ocular anatomy. The
tear film maintains an optically uniform surface, lubricates
and nourishes eye tissue, washes out cellular debris and
foreign bodies, and also protects from bacterial infections
[14–16].
Inflammationisacentralfeatureofocularsurfacedisease.
An association between ocular symptoms and activation
of T lymphocytes has been established in patients with
Sj¨ ogren’s syndrome [3]. Today it is understood that a local
autoimmune occurrence could appear irrespective of sys-
temic autoimmune disease. Conjunctival inflammation is
manifested by infiltration of inflammatory cells and upreg-
ulated expression of immune markers. Hyperosmolar stress
has proinflammatory effect. A better understanding of the
immunopathologicalmechanismsofocularsurfacedisorders
etiology corresponds with modification of applied therapy
[15, 16].
5. Risk Factors
As previously noted, risk factors for dry eye include female
sex, older age, postmenopausal estrogen therapy, computer
use, contact lens wear, a diet low in omega-3 essential fatty
acidsorahighratioofomega-6toomega-3fattyacids,refrac-
tive surgery, vitamin A deficiency, radiation therapy, bone
marrow transplantation, hepatitis C, and certain classes of
systemic and ocular medications, including antihistamines.
Vitamin A deficiency is a well-recognized risk factor for
dry eye, and the etiology includes inadequate intake due
to alcohol-related nutritional deficiency, stomach surgery,
malabsorption, eating disorders, and a vegan diet.
Other risk factors include diabetes mellitus, human im-
munodeficiency virus, HIV and human T cell lymphotropic
virus-1 infection, connective tissue diseases, systemic cancer
chemotherapy, and medications such as isotretinoin, antide-
pressants, anxiolytics, beta-blockers, and diuretics. However,
a comprehensive study of these factors is still lacking.
C o n fl i c t i n gr e s u l t sh a v eb e e nr e p o r t e do nt h ea s s o c i a t i o n
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smoking, caffeine, acne, and menopausal status. Likewise,
very few reports exist on the risk of dry eye with use of oral
contraceptives and during pregnancy [5, 9, 10, 17–19].
6. Symptoms
It is often incorrectly assumed that symptoms of dry eye
are the main feature of this disease, whereas unfortunately
they do not always correspond with diagnostic test results
except in severe cases. The symptoms that patients describe
are the same ocular sensations felt in other ocular surface
disorders, namely, reports of a gritty, sandy foreign body
sensation and visual disturbances. Visual complaints are
highly prevalent among dry eye patients usually described
as blurry vision that clears temporarily upon blinking [6].
These transient changes, resulting from disrupted tear film
in the central cornea, can be profound with marked drops
in contrast sensitivity and visual acuity thereby affecting
workplace productivity and vision-related quality of life [6,
19].
7. Diagnostic Procedures
The diagnosis of ocular surface disease is based on the
patient’ssymptomsandmedicalhistorywhichshouldinclude
questions about topical and systemic medications used and
possible exposure to aggravating factors. Currently available
diagnostic tests and external examinations are also indis-
pensable for every practitioner in order to reach the decision
on the most suitable treatment [1]. Symptom questionnaires
allowforrapidandefficientcollectionofrelevantinformation
and can facilitate diagnosis of ocular surface disorders.
Questionnaires and dry eye index scores can be useful to
detect the presence of dry eye and to evaluate the effect of
therapeutic treatment. Several questionnaires are available,
with the most common being the Ocular Surface Disease
Index (OSDI) [20]. However, there is still no standardized
dry eye disease questionnaire that is universally accepted.
Afterpatient’smedicalhistoryisobtainedandquestionnaires
administered, clinical examination of the anterior segment
and objective tests are necessary to confirm the diagnosis of
dry eye [2, 21].
7.1. Objective Testing. Objective tests for dry eye can be
divided into tests that examine the tears and those that
e x a m i n et h ei n t e g r i t yo ft h eo c u l a rs u r f a c e .Th ef o r m e rc a n
further be subdivided into tests that investigate the quantity,
quality, or functional properties of tears.
7.2. Tear Quality. Some authors consider that the determi-
nation of tear osmolarity is significant in dry eye diagnosis;
however, it requires expert technical support, and its use
has to date been confined to specialized laboratories [22].
The appearance of new more affordable osmometers has
expanded their use in everyday practice [23]. The most
common test for determining tear film quality in use today
is the tear breakup time (TBUT) which is described later in
this paper.
7.3. Tear Quantity. The most widely used technique to eval-
uate tear quantity is the Schirmer test 1, performed without
anesthesia. In this test, a 5×3 5mm strip of filter paper that
is bent 5mm from the end is placed under the lower eyelid
on the temporal side. The strip is kept in place for 5 minutes
a n dt h e nt h el e n g t ho ft h em o i s t e n e ds t r i pi sm e a s u r e d .A
result yielding less than 5mm shows aqueous tear deficiency.
Insertion of the strip for 5 minutes may cause discomfort
with reflex tears secretion. Therefore, as an alternative, some
practitioners keep the paper in place for 2 minutes or apply a
topical anesthetic prior to placing the strip (Schirmer II) [14,
24]. Another noninvasive method used is the tear meniscus
height measurement on the lower eyelid, whereby a height
lower than 0.2mm is associated with tear deficiency [25].
7.4. Stains and Dyes of the Ocular Surface. Fluorescein is
useful in assessing dry eye where its application can deter-
minetheintegrityofthecornealandconjunctivalepithelium.
The normal epithelium does not stain; however, when the
mucous layer is absent, the dye penetrates and stains the
epithelium.Evaluationafter2minutesisrecommendedsince
prematureexaminationofthesurfacemayunderestimatethe
degr eeofdamage[2,14].Lissaminegreenisanotherdyeused
t oe v a l u a t et h ea n t e r i o rs e g m e n ta n di su s e dt os t a i nd e a d
or degenerated cells and produces less irritation compared
with rose bengal dye. Grading ocular surface staining after
application of vital dyes is a central component of dry eye
diagnosis [26]. Fluorescein is also used for classic tear film
stabilitytests.Fluoresceinisappliedintothelowerfornix,and
the patient is first asked to blink several times and then to
avoidblinking.Abroadslit-lampbeamwithcobaltbluefilter
is used to scan the tear film. The presence of black spots or
lines indicates the appearance of dry spots in the tear film
[27]. Tear film breakup time (TBUT) is the interval between
theblinkandtheappearanceofthefirstrandomlydistributed
dry spot. A TBUT of less than 10 seconds is considered
abnormal [14, 27].
7.5. Additional Tests. Patients with keratoconjunctivitis sicca
often have a decreased eyelid blink rate as result of dimin-
ished corneal sensitivity due to ocular surface inflammation.
However, reduced corneal sensation is also observed after
refractive surgery as with normal aging [28]. The ocular
protectionindex(OPI)wasdesignedinanattempttoprovide
a combined measurement of tear film instability and the
interblink interval (IBI). It is calculated by dividing the
number of eyelid blinks in 1 minute by 60 whereby the
normal IBI is between 10 and 12 seconds. Dividing the TBUT
value by the IBI, the OPI value is obtained. OPI values
less than 1 suggest that the tear film destabilizes between
blinks whilst OPI values of 1 or higher seem to correlate
with patient symptoms [29]. Additional useful tests include
conjunctival impression cytology (to evaluate the goblet
cells),brushcytology(toanalyzethepossibleinflammationof
theocularsurface),andmeasuringthequantitiesoflysozyme
and lactoferrin in the tears. Decreases in the concentration
of these two major lacrimal proteins secreted by the lacrimal
glands in tear film indicate lacrimal gland dysfunction [30].4 BioMed Research International
7.6. Emerging Technologies. Newer research attempts to
detect and develop new diagnostic technologies that will
show promise for advancing our ability to investigate, mon-
itor, and diagnose dry eye disease in the future. There
is particular interest in noninvasive or minimally invasive
technologies, namely, various instruments that can detect
optical changes in tear film consistency without touching the
e y et h a tc o u l db ea d a p t e df o re v e r y d a yc l i n i c a lu s e .R e s e a r c h
is continuously striving to develop and improve technologies
thatallowchangesintearsattheocularsurfacetobedetected
w h i l ec a u s i n gt h el e a s td i s t u r b a n c et ot e a rfi l md y n a m i c s
during sampling [31].
8. Complications of Untreated Dry Eye
Since tears protect the ocular surface from infection in
severe cases of untreated dry eye syndrome, the associated
inflammation can damage the conjunctiva and the cornea
with an increased risk of eye infection. Fortunately, most
cases of dry eye related conjunctivitis are mild and do not
need specific treatment. If inflammation however becomes
severe and chronic, timely and appropriate therapy must be
applied prior to damages of the corneal surface which leads
toirreparableulcerationorscarring.Thesecomplicationscan
producemoreseveresymptomssuchasextremesensitivityto
light, pain, red eyes, and loss of vision [14, 32].
9. Treatment
The prime goal of treatment of the ocular surface disorders
includes relief of symptoms, improvement of visual acuity
and quality of life, restoration of ocular surface and tear
film,andcorrectionofunderlyingdefects.Treatmentoptions
comprise of hygiene and life style changes, artificial or autol-
ogous serum tear use, and anti-inflammatory drug therapy,
as well as physical and surgical procedures to increase tear
retention. Treatment should be adjusted to incorporate the
patient’s response and must maintain a balance between
efficacy, safety, and patient convenience [14].
The simplest and most effective way to relieve symptoms
of dry eye is a lifestyle change. Patients should be advised to
avoid long exposure to computers, TV, and reading which
is associated with a reduced blink rate and thus increased
evaporation.Theuseofartificialtearsandshortbreaksduring
these activities are recommended. Humidification of air in
t h eh o m ea n dw o r kp l a c ec o u l da l s oa l l e v i a t eu n d e s i r a b l e
effects. Avoidance of hot, windy, low-humidity, and high-
altitude environments as well as smog and smoke is also
advisable [14, 33].
Eyelid hygiene, warm compresses, and topical antibiotics
when needed are essential for chronic blepharitis and mei-
bomian gland dysfunction treatment which can be associ-
ated with tear dysfunction. These measures reduce bacterial
induced changes in the lipid component of the tear film,
w h i c hi nt u r nr e d u c e se v a p o r a t i v et e a rl o s s[ 33].
It has been shown that a higher dietary intake of omega-
3 fatty acids with lower dietary ratio of omega-6 to omega-3
fatty acids as well as use of supplements containing linoleic
a n dg a m m a - l i n o l e i ca c i dd e c r e a s e st h er i s ka s s o c i a t e dw i t h
dry eye symptoms [34, 35].
Tear supplements provide only temporary relief of dry
eye symptoms and usually contain preservatives which can
irritate the eye and additionally exacerbate symptoms. Thus
patients requiring tear supplements more than 4 times a day
should be prescribed preservative-free products. Artificial
tears cannot replace the cytokines and growth factors which
are comprised in normal tears and produced by normal-
functioning lacrimal glands and thus do not have direct anti-
inflammatory effect [14, 33].
Keeping in mind that inflammation is a key component
o ft h ep a t h o g e n e s i so fd r ye y e ,t h ee ffi c a c yo fs o m ea n t i -
inflammatory agents for dry eye disease treatment has been
investigated. This form of therapy may be used for patients
who have corneal disease and have persistent symptoms
despite extensive use of artificial tears. The most widely used
anti-inflammatory agents are topical corticosteroids, tetra-
cyclines, cyclosporine A, and in some cases in patient with
Sj¨ ogren’ssyndromepilocarpine.Beforeusingthismedication
possible side effects should be assessed with respect to their
potential benefit [14, 15, 33].
Autologous serum tears is the fluid component of full
blood that remains after clotting and contains fibronectin,
vitamin A, cytokines, growth factors, and anti-inflammatory
substances. Kojima et al. observed the benefit of 20% autolo-
gous serum solution showing symptom relief, improvement
of TBUT test, and rose-bengal staining score in patients with
dry eye disease. It should however be noted that this kind of
treatmentshouldbereservedformanagementofseverecases
only [36]. Kinoshita et al. in their randomized, multicenter
phase 3 study showed that administration of 2% rebamipide
was effective in improving both the objective signs and sub-
jective symptoms of dry eye [37]. Those findings, in addition
to thewell-toleratedprofileof2%rebamipide,clearly showed
that it is also an effective therapeutic method for dry eye.
Punctual plugs relieve dry eye symptoms in patients with
Sj¨ ogren’s syndrome, filamentary keratitis, chronic Stevens-
Johnson syndrome, trachoma, neurotrophic and diabetic
keratopathy, keratitis sicca, and in patients with dry eye
after refractive surgery. Obstruction or inflammations of the
lacrimal canaliculi or ducts as well as active blepharitis is
a contraindication for their application. Permanent surgical
punctual occlusion is an alternative to use of punctal plugs
[38].
Moisture-retaining eye wear protects the eyes from envi-
ronmental drying and increases periocular humidity [39].
Hydrophilic bandage contact lenses may be considered for
cornealsurfaceprotectionorpainrelieforasanaidtocorneal
reepithelization. The lenses act as a reservoir for sustained
hydration, serve as a barrier that protects the traumatized
cornea, and provide splitting effect for corneal healing [40].
Surgical procedures suitable for treatment of severe dry
eye include lid procedures (permanent punctal closure usu-
ally with cautery and tarsorrhaphy) and conjunctival pro-
cedures (conjunctival transplantation, amniotic membrane
transplant, free conjunctival graft, and stem cell replace-
ment).BioMed Research International 5
To surmise, the recommendations of the Dry Eye Work-
shop based on disease severity consist of four levels of
treatment [14, 33].
Level 1 (dry sensation, burning). Education and environmen-
tal/dietary modifications; elimination of offending systemic
medications; use of preserved artificial tear substitutes, gels,
and ointments; and eyelid therapy.
Level 2 (itching, pain, photophobia). Use of nonpreserved
artificial tear substitutes; anti-inflammatory agents (topical
corticosteroids, topical cyclosporine A, topical or systemic
omega-3 fatty acids); tetracyclines (for meibomianitis or
rosacea); punctal plugs (after the inflammation has been
brought under control); secretagogues (pilocarpine); and
moisture chamber spectacles.
Level 3 (red eyes, foreign body sensation, pain, blurred vision).
Application of autologous serum or umbilical cord serum;
prescription of contact lenses; or permanent punctal occlu-
sion.
Level 4 (blepharospasm, risk of corneal perforation). Prescrip-
tion of systemic antiinflammatory agents and surgery (lid
surgery, tarsorrhaphy, mucous membrane grafting, salivary
gland duct transposition, amniotic membrane transplanta-
tion).
10. Conclusion
Dry eye is a multifactorial disease of the tears and ocular
surface with symptoms that often fail to correspond to
diagnostic testing. It is a widespread problem that may often
be overlooked since it is not a common cause of permanent
visual morbidity [8, 16]. However, newer concepts suggest
thatdryeyesyndromecanhaveasignificantimpactonvisual
function diminishing the everyday quality of life [19]. If left
untreated, the patient may experience not only discomfort
and visual disturbances but also ocular inflammation and
scarring of the corneal surface with permanent damage
[16, 19]. Management of ocular surface disorders requires
thorough history and ophthalmological examination. The
incorporationofaquestionnairemayfacilitatetheevaluation
of patients and aid in setting a diagnosis. A variety of
treatmentmodalitiesarecurrentlyavailableandtheselection
of treatment can be simplified by classifying symptoms on
a continuum from mild to severe and thereby choosing
therapies that target the underlying inflammatory process
with the goal of restoring the normal tear film and function.
New research attempts to detect and develop new and
promising diagnostic technologies that will further advance
our ability to investigate, diagnose, and treat dry eye disease
in the future.
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